The President of Venezuela, Nicolas Maduro, has said that he will give the COVAX system an ultimatum this week to send the country's share of COVID-19 vaccines as all pending payments had been made to COVAX, the global vaccine sharing facility, Reuters news agency reported on Monday.
COVAX reportedly informed Venezuela in June 2021 that the last four payments had been blocked by UBS. These payments cover the USD120m fees that have already been made.
Maduro was quoted as saying in a live appearance on state television that officials had been instructed to "give the COVAX system an ultimatum: they send us the vaccines or they give us the money back, period."
Venezuela is facing US sanctions that affect its access to the global financial system and reportedly relied on domestic banks to make part of the payment to the COVAX system with foreign currency.
The country has expressed interest in receiving the Johnson & Johnson (NYSE:JNJ) and Novavax (Nasdaq:NVAX) vaccines through COVAX.
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results